Neurocrine Biosciences
$143.18Change from previous close: +1.76%Absolute change: +$2.47
At a glance
- Revenue growth
- +21.45%
- 2025 vs 2024
- Net income growth
- +40.23%
- 2025 vs 2024
- Net margin
- 16.7%
- 2024: 14.5%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | 136 | 146 | 388 | 228 | 102 | — |
| Depreciation and amortization | 24.8 | 7.3 | 7.5 | 7.7 | 7.3 | — |
| Capital expenditure | -7.8 | -9.1 | — | -13.2 | -12.5 | -10.7 |
| Investing cash flow | -135 | -506 | -52.9 | -197 | -29.0 | — |
| Financing cash flow | 63.4 | -86.1 | 37.3 | 45.6 | -3.3 | — |
| Share repurchases | -12.0 | -54.0 | 0.0 | 0.0 | -17.7 | — |
| Debt repaid | — | — | 0.0 | 0.0 | — | — |
| Effect of exchange rates | — | — | 0.0 | -0.2 | — | — |
| Net change in cash | 64.4 | -447 | 373 | 76.4 | 69.7 | — |
| Free cash flow | 129 | 137 | 391 | 214 | 89.5 | — |